#USA #Sausalito #Revelation Partners #Eric Shiozaki #healthcare secondaries

Revelation Partners Strengthens its Investment Team

Revelation Partners, a prominent player in the healthcare secondaries investment sector, has recently announced the promotion of Eric Shiozaki, Ph.D., to partner. This strategic move aims to enhance the firm's capabilities in securing investment opportunities specifically within the biotechnology and medical device industries.

Established in Sausalito, California, Revelation Partners manages an impressive portfolio with over $1.5 billion in committed capital. The firm is dedicated to providing liquidity and growth capital to a wide range of stakeholders within the private healthcare market, including investors, companies, and both limited and general partners.

Eric Shiozaki's journey at Revelation began in 2024 when he joined as a venture partner, where he focused on tapping into high-potential investments in biotech and medical devices. His promotion comes at a pivotal time as the firm is experiencing record levels of deal flow, making his expertise particularly valuable in identifying and underwriting compelling investment opportunities.

Michael Boggs, managing partner at Revelation Partners, stated, "Eric's scientific background combined with his extensive experience in both public and private biotech investments deepens our knowledge and differentiates our investment strategies within this competitive market. His contributions have been instrumental in our ability to navigate the rapidly expanding landscape of healthcare investments."

Shiozaki brings with him over 25 years of experience in healthcare investing and biomedical research. He previously held partnerships at DCVC Bio, an early-stage life sciences venture capital fund, and Novo Holdings, where he was responsible for managing a long-only public equities fund with a sharp focus on growth-stage biotech and medical device firms. Before these roles, he was a director at Apposite Capital, where he made significant investments in healthcare secondaries, and started his venture investing career at Burrill & Company as an associate.

Trained initially as a structural biologist, Shiozaki has a strong academic foundation. He holds a Bachelor of Arts in Biophysics from Johns Hopkins University and a Ph.D. in Molecular Biology from Princeton University. His scholarly contributions include publications in top-tier scientific journals, and he has been recognized as a Leukemia & Lymphoma Society Post-Doctoral Fellow.

As Revelation Partners continues to navigate and lead in the healthcare sector, the firm remains focused on delivering tailored solutions for liquidity-seeking shareholders and growth-capital-seeking companies. With the addition of Shiozaki to the leadership team, Revelation Partners is well-positioned to harness its deep market knowledge and extensive industry network to empower its clients and stakeholders.

For more information about Revelation Partners and their investment strategies, visit Revelation Partners.